ACET — Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 152
- Website: https://www.adicetbio.com
Latest SEC filings for ACET
- 8-K — 2026-09-08
- 8-K — 2026-09-01
- SCHEDULE 13G/A — 2026-08-14
- 8-K — 2026-08-05
- 10-Q — 2026-08-05
- 8-K — 2026-06-18
- 10-K/A — 2026-05-20
- 8-K — 2026-05-13
- S-8 POS — 2026-05-13
- 10-Q — 2026-05-13
Latest ACET news
- — Adicet Bio's Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months (marketbeat.com)
- — Wedbush raises Adicet Bio stock price target on lupus trial data - Investing.com India (Investing.com India)
- — Adicet Bio (NASDAQ:ACET) Stock Gets Price Target Boost from HC Wainwright - MarketBeat (MarketBeat)
- — Wedbush raises Adicet Bio stock price target on lupus trial data - Investing.com UK (Investing.com UK)
- — Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis Transcript (seekingalpha.com)
- — Adicet Bio Advances Prula-cel Toward Pivotal Lupus Trial - tipranks.com (tipranks.com)
- — Every patient in Adicet's lupus study stopped immune-suppressing drugs - Stock Titan (Stock Titan)
- — Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis (businesswire.com)
- — Understanding the Setup: (ACET) and Scalable Risk - Stock Traders Daily (Stock Traders Daily)
- — Adicet Bio (NASDAQ:ACET) Earns Buy Rating from HC Wainwright - MarketBeat (MarketBeat)
Educational tool only — not investment advice.